id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268369-yj7m0n0f	Wang, Keyang	Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine	2006-03-15		.txt	text/plain	5703	306	53	The influenza hemagglutinin protein (HA), the active ingredient in the current vaccine, can be expressed in insect cells using the baculovirus expression vector system and purified rapidly. On the other hand, the recombinant protein-based approach involves production of viral antigens such as HA and NA in cell culture with recombinant DNA technology and utilization of the purified antigens as the active ingredients in the vaccine. The rHA influenza vaccines developed using the baculovirus-insect cell expression system has been tested in several Phase I and Phase II human clinical trials involving over 1200 subjects that demonstrated safety, immunogenicity and efficacy [19] [20] [21] [22] [23] . On the other hand, most of RBCs were bound to the insect cells infected with baculovirus containing the HA gene derived from influenza strain A/New Caledonia/20/99 (H1N1) (Fig. 1b) .	./cache/cord-268369-yj7m0n0f.txt	./txt/cord-268369-yj7m0n0f.txt